Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

By P. Coulie, B. Eynde, P. Bruggen, T. Boon. Nature Reviews. Cancer, 2014

1,055 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/6e6ae338ae1f76e54bddb2f7bb55df62e2b34a4f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Artificial intelligence as the next step towards precision pathology (2020, background): “Due to changed protein expression by the tumour, the immune cells can identify the tumour cells and initiate an immune response [25, 26].”
Radiomics: the bridge between medical imaging and personalized medicine (2017, positive): “For a robust and vigorous immune response to be elicited, the activation of antigen-specific T-cells coupled with memory effects is required 93 .”
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018, background): “In fact, only a minority of mutations generate peptides that are properly processed and loaded on to MHC complexes, and even fewer are able to be recognized by T cells [47, 48].”
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications (2020, background): “Novel technologies to dissect tumor-infiltrating immune cells at the single-cell level As the key component of adaptive immunity, T cells have been the core pillar of immunotherapy owing to their specificity for antigen recognition and their potent tumor-killing ability.(96) TILs are a heterogeneous”
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review (2018, background): “On the other hand, an increase of CTL recruitment and function is diversely correlated to the number of Tregs in the TME (D. Wang, Quiros, et al., 2018), and it converts the milieu from immunosuppressive to immunostimulatory state (Deng et al., 2018).”
Immune escape mechanisms as a guide for cancer immunotherapy (2014, background): “Tumor antigens can be derived from viral proteins, proteins encoded by cancer-germline genes, differentiation antigens, and proteins arising from somatic mutations or gene rearrangements (10).”
Advances in immunotherapy for hepatocellular carcinoma (2021, background): “I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”